Noncompromised penicillin-resistant pneumococcal pneumonia CBA/J mouse model and comparative efficacies of antibiotics in this model.
about
Method for inducing experimental pneumococcal meningitis in outbred miceEfficacy of TAK-457, a novel intravenous triazole, against invasive pulmonary Aspergillosis in neutropenic mice.Efficacy of β-Lactam-plus-Macrolide Combination Therapy in a Mouse Model of Lethal Pneumococcal PneumoniaManagement of infections due to antibiotic-resistant Streptococcus pneumoniaeDevelopment of a new experimental model of penicillin-resistant Streptococcus pneumoniae pneumonia and amoxicillin treatment by reproducing human pharmacokinetics.Pharmacodynamics of glycopeptides in the mouse peritonitis model of Streptococcus pneumoniae or Staphylococcus aureus infectionIn vitro and in vivo antibacterial activities of L-084, a novel oral carbapenem, against causative organisms of respiratory tract infections.Penicillin pharmacodynamics in four experimental pneumococcal infection models.Development and characterization of a long-term murine model of Streptococcus pneumoniae infection of the lower airways.Pharmacodynamic assessment of clarithromycin in a murine model of pneumococcal pneumoniaIn vitro and in vivo antibacterial activities of DK-507k, a novel fluoroquinolone.Efficacy of calcium-EDTA as an inhibitor for metallo-β-lactamase in a mouse model of Pseudomonas aeruginosa pneumonia.In vivo efficacies and pharmacokinetics of DX-619, a novel des-fluoro(6) quinolone, against Streptococcus pneumoniae in a mouse lung infection model.Determination of vancomycin minimum inhibitory concentration for ceftazidime resistant Streptococcus pneumoniae in IranIn vitro and in vivo pharmacokinetics-pharmacodynamics of GV143253A, a novel trinem.Trovafloxacin, a new fluoroquinolone with potent activity against Streptococcus pneumoniae.In vitro and in vivo antibacterial activities of CS-940, a new fluoroquinolone, against isolates from patients with respiratory infections.Pharmacodynamics of S-3578, a novel cephem, in murine lung and systemic infection modelsA strain-independent method to induce progressive and lethal pneumococcal pneumonia in neutropenic miceVirulence-suppressing effects of linezolid on methicillin-resistant Staphylococcus aureus: possible contribution to early defervescenceIn vitro and in vivo antibacterial activities of DC-159a, a new fluoroquinoloneAnimal models of Streptococcus pneumoniae diseasePharmacodynamic assessment of gatifloxacin against Streptococcus pneumoniae.In vivo efficacy of telithromycin (HMR3647) against Streptococcus pneumoniae and Haemophilus influenzaeEfficacy of CS-834 against experimental pneumonia caused by penicillin-susceptible and -resistant Streptococcus pneumoniae in mice.In vitro and in vivo antibacterial activities of S-4661, a new carbapenem.In vivo activity of HSR-903, a new fluoroquinolone, against respiratory pathogens.In vivo antibacterial activities of sanfetrinem cilexetil, a new oral tricyclic antibiotic.Pharmacodynamics of a novel des-F(6)-quinolone, BMS-284756, against Streptococcus pneumoniae in the thigh infection model.Treatment of experimental pneumonia due to penicillin-resistant Streptococcus pneumoniae in immunocompetent ratsIn vivo efficacy of a new quinolone, DQ-113, against Streptococcus pneumoniae in a mouse model.
P2860
Q24803416-E3C6B906-61DB-4CFE-A9D7-CC7E27AE3506Q28345150-0D224B60-8AB8-4000-9FF6-1633A58395C4Q28390204-A6AE2D55-5508-4B8D-B909-0F3B492414C9Q33975374-0FB62648-F86B-4F6F-8810-FA77115A63D1Q33977871-E80BD253-4A17-47E1-88B2-A55A62AA5AD4Q33979426-AE22FCE7-C3D4-404E-B86E-96EE39CDFE31Q33981178-6FE81178-6173-4ABD-A3D1-1183F159F624Q33981846-482A26F9-D4AD-44BF-9A2B-7ACE80F9AA06Q34058974-FBCA4096-93A4-4494-A00D-DF766958F1F3Q34106566-C33FDC64-DE25-4900-812A-05CFC104B900Q34230118-536267BD-8D78-437E-A2DF-9480B9D44DF6Q34290145-3C0E437F-4786-4052-9A99-C96D59223A19Q34301493-537DFF14-102B-4727-BEBB-51FE037B9B33Q34667511-1E40BBB5-9217-4224-854F-74843947B68EQ34824344-5A95DB02-252F-459F-A806-6ADDD1977762Q35133005-86835C85-6B77-4CCD-854A-5E78BE19C40CQ35139147-57E25044-06DB-4072-A070-B87D3AF4B7A6Q35547159-63F417C6-2DA9-488E-9021-59A50FE940B5Q35761235-FD832484-7189-4D29-AFF7-0AA480491B15Q35867280-D2220AC6-5B39-4157-A702-597C5AB758CEQ36422607-2090F819-26AF-419A-BFBF-8F88A34EE010Q37293669-B961B0FE-DC5D-42B5-AEA4-3A90A40E3655Q39477806-444EF454-080A-45C0-B73C-31F4A06D6D7FQ39478973-DAF67722-F5D7-48A0-AEB5-C53F406875E4Q39556898-4BB0DB75-F094-4CA8-90AB-934FEAAF23F9Q39556956-DCD24A3B-532A-489F-8EE6-298326682141Q39557374-53A9636F-A612-4ED8-80A3-BE6B80B8BCD3Q39558148-8A957399-8433-4415-B401-EF80A7F9C1D7Q39746333-87BBBED5-5D86-4033-A303-6B26FD3803DBQ39783946-DAA60663-0534-4C42-8A30-46B8C7C03979Q40345316-695AD4E5-CC44-4668-A2CB-FE3DA6C75F4B
P2860
Noncompromised penicillin-resistant pneumococcal pneumonia CBA/J mouse model and comparative efficacies of antibiotics in this model.
description
1996 nî lūn-bûn
@nan
1996 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
Noncompromised penicillin-resi ...... of antibiotics in this model.
@ast
Noncompromised penicillin-resi ...... of antibiotics in this model.
@en
type
label
Noncompromised penicillin-resi ...... of antibiotics in this model.
@ast
Noncompromised penicillin-resi ...... of antibiotics in this model.
@en
prefLabel
Noncompromised penicillin-resi ...... of antibiotics in this model.
@ast
Noncompromised penicillin-resi ...... of antibiotics in this model.
@en
P2093
P2860
P356
P1476
Noncompromised penicillin-resi ...... s of antibiotics in this model
@en
P2093
Matsumoto T
Miyazaki H
Takashima K
Yamaguchi K
P2860
P304
P356
10.1128/AAC.40.6.1520
P407
P577
1996-06-01T00:00:00Z